BBIO vs NDAQ · rev $438.2M vs P/E 41, rev $2.53B
BridgeBio Pharma Inc (BBIO) versus Nasdaq Inc (NDAQ) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
Nasdaq Inc (NDAQ) is a financial data & stock exchanges company listed on US.
Latest reported BBIO revenue for 2026-06-30 was $438.2M. Net income was -$322.4M. BBIO currently screens at market cap $13.24B.
Latest reported NDAQ revenue for 2026-06-30 was $2.53B. Net income was $507.0M. Revenue was up 18.5% from 2026-03-31 to 2026-06-30. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
BBIO currently screens at market cap $13.24B. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
Not investment advice. Open the BBIO and NDAQ stock pages for the full models.
Not investment advice.